Evidence map›Paper›PMID 32637957›Full record

ArticlebioRxiv : the preprint server for biology2020

Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.

Flavia Chiuppesi, Marcela d'Alincourt Salazar, Heidi Contreras, Vu H Nguyen, Joy Martinez, Soojin Park, Jenny Nguyen, Mindy Kha, Angelina Iniguez, Qiao Zhou and 10 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Flavia ChiuppesiDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Marcela d'Alincourt SalazarDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Heidi ContrerasDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Vu H NguyenDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Joy MartinezDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Soojin ParkDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Jenny NguyenDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Mindy KhaDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Angelina IniguezDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Qiao ZhouDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Teodora KaltchevaDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Roman LevytskyyDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Nancy D EbeltDepartment of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.
Tae Hyuk KangDepartment of Genomic core facility, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.
Xiwei WuDepartment of Genomic core facility, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.
Thomas RogersUniversity of California San Diego, School of Medicine, Division of Infectious Diseases and Global Public Health, 9500 Gilman Dr, La Jolla, CA 92093; Scripps Research, Department of Immunology and Microbiology, 10550 N Torrey Pines Rd, La Jolla, CA 92037.
Edwin R ManuelDepartment of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte CA 91010, USA.
Yuriy ShostakResearch Business Development, City of Hope, Duarte CA 91010, USA.
Don J DiamondDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
Felix WussowDepartment of Hematology and Transplant Center, City of Hope National Medical Center, Duarte CA 91010, USA.
City Of Hope National Medical Center · USCity of Hope · USScripps Health · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5M
Project 3: Mapping the Evolution of Chronic Transplant Injury in the Context of CMV InfectionU19AI128913 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOFFMANN, ALEXANDER · 2017 to 2021
$11.2M
CMVPepVax to Protect HCT Recipients from Cytomegalovirus InfectionR01CA181045 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DIAMOND, DON J · 2014 to 2018
$3.6M
NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA033572NCI NIH HHS P50 CA107399NCI NIH HHS R01 CA181045NIAID NIH HHS U19 AI128913
6 · The paper itself

Abstract

Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a novel vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.

Identifiers

PMID32637957
PMCPMC7337387
OpenAlexW3038594161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.